FibromyalgiaNCT03841227
Effect of tDCS in Intrinsic Functional Brain Connectivity Assessed by Functional Magnetic Resonance in Fibromyalgia
A study testing Active-tDCS in people with Fibromyalgia, run by Hospital de Clinicas de Porto Alegre at 2 sites in Brazil.
Trial summary
Considering the central component of fibromyalgia (FM), the focus of research on current therapeutic approaches has been techniques that may modify the dysfunctional neuroplasticity process, such as transcranial direct current (tDCS) stimulation in order to counteract the dysfunction responsible for triggering and… Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Fibromyalgia
- What is being tested?
- Active-tDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 2 sitesBrazil
- Study dates
- 1 Aug 2018to 1 Mar 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Literate
- Female, between 18 and 65 years old
- With the diagnosis of fibromyalgia according to the criteria of the American College of Rheumatology (2010-2016)
- Pain score equal to or greater than six on the Numerical Pain Scale (NPS 0-10) on most days of the last 3 months.
- Give informed consent to participate after the initial evaluation.
Who cannot join
- Living outside the city of Porto Alegre, RS, Brazil
- Pregnancy
- Severe Mental Illness
- tDCS contraindications
- Magnetic resonance imaging (MRI) contraindications
Trial locations and contacts
2 sites in 1 country.
Brazil2 sites, 2 recruiting
- Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90.450-120
Wolnei Caumo, PhD, +5551 3359 8083, wcaumo@hcpa.edu.br
Wolnei Caumo, PhD
- Recruiting
Hospital de Clinicas e Porto Alegre (HCPA)
Porto Alegre, Rio Grande do Sul, 90035-003
Wolnei Caumo, 55 51 99813977, caumo@cpovo.net
Wolnei Caumo
About this study
Official title: Effect of Transcranial Continuous Current Neuromodulation in Intrinsic Functional Brain Connectivity Assessed by Functional Magnetic Resonance Imaging (fMRI) in Fibromyalgia: A Randomized, Double-blind Controlled Trial
Considering the central component of fibromyalgia (FM), the focus of research on current therapeutic approaches has been techniques that may modify the dysfunctional neuroplasticity process, such as transcranial direct current (tDCS) stimulation in order to counteract the dysfunction responsible for triggering and maintain the symptoms of FM. Although this technique is gaining space in research and in the clinical scenario, many questions remain to be answered, such as time of treatment, place to be stimulated and neurophysiological clarification of the mechanisms involved.
Based on the presented scenario, the present project was organized, being a double-blinded parallel randomized controlled trial with 20 female patients with FM diagnosed according to the criteria of the American Society of Rheumatology (2010 - reviewed in 2016) between 19 and 65 years of age, randomized to receive active or simulated anodic pole over the left dorsolateral prefrontal cortex (DLPFC) (10 patients in each group). Twenty 20-minute sessions, with a current intensity of 2 milliamperes, will be performed.
Read more
In order to respond to the objectives of this study, the IFC will be evaluated before and after the intervention, through rs-fMRI using seed-based correlation analysis (SCA). The investigators have a secondary objective to correlate structural connectivity through the technique of diffusion tensors imaging (DTI) with measures of pain, functional capacity, depressive symptoms and catastrophism to pain.
The hypothesis is that in FM there is a syndrome of dysfunction in basal intrinsic functional connectivity (IFC) and that the tDCS has a neuromodulatory effect capable of reducing connectivity between brain areas related to chronic pain and other neuropsychiatric components of FM, such as the ventrolateral thalamus, cortex motor, prefrontal cortex, insular cortex, hippocampus, periaqueductal gray matter, among others. The investigators believe that a higher cortico-thalamic IFC and between regions with high density of opioid receptors have a positive predictive response in the treatment of tDCS.
Read the detailed description
Fibromyalgia (FM) is a syndrome that is characterized by generalized musculoskeletal pain, fatigue, unrepairable sleep, cognitive alterations, depressive and neurovegetative symptoms, whose neurobiological process is multiple and complex. Although it is of great relevance to the individual and to society, this pathology often does not receive the necessary attention by the organs that define the priorities of health care. Population prevalence, according to the criteria of the American Society of Rheumatology, reaches 5.4%, and the costs of care, taxes and early retirement due to disability are estimated at more than the US $ 29 billion per year in the United States. It is known that conventional pharmacological therapies produce insignificant responses in more than 50% of patients. It is postulated that these high rates of failure are due in part to a lack of knowledge about pathophysiological mechanisms. What is known so far is that the peripheral mechanisms contribute to the FM picture, but dysfunction in central neurobiological pathways surely commands the process, perpetuating the dysfunctional process that includes central sensitization (CS). CS comprises the symptoms of fibromyalgia syndrome that culminates in a state of hypersensitivity that expresses the imbalance of the excitation/inhibition processes that sustain this condition of non-pathological pain. Functional alterations of the motor cortex and its connections with subcortical structures that constitute the neuromatrix of pain have now been demonstrated. Functional magnetic resonance imaging (fMRI), using the resting-state fMRI (rs-fMRI) technique, has also demonstrated that high intrinsic functional connectivity (IFC) is related to pain intensity on FM.
Considering the central component of FM, the focus of research on current therapeutic approaches has been techniques that may modify the dysfunctional neuroplasticity process, such as transcranial direct current (tDCS) stimulation in order to counteract the dysfunction responsible for triggering and maintain the symptoms of FM. Although this technique is gaining space in research and in the clinical scenario, many questions remain to be answered, such as time of treatment, place to be stimulated and neurophysiological clarification of the mechanisms involved.
Based on the presented scenario, the present project was organized, being a double-blinded parallel randomized controlled trial with 20 female patients with FM diagnosed according to the criteria of the American Society of Rheumatology (2010 - reviewed in 2016) between 19 and 65 years of age, randomized to receive active or simulated anodic pole over the left dorsolateral prefrontal cortex (DLPFC) (10 patients in each group). Twenty 20 minute sessions, with a current intensity of 2 milliampere, will be performed.
In order to respond to the objectives of this study, the IFC will be evaluated before and after the intervention, through rs-fMRI using seed-based correlation analysis (SCA). The investigators have a secondary objective to correlate structural connectivity through the technique of diffusion tensors imaging (DTI) with measures of pain, functional capacity, depressive symptoms and catastrophism to pain.
The hypothesis is that in FM there is a syndrome of dysfunction in basal IFC and that the tDCS has a neuromodulatory effect capable of reducing connectivity between brain areas related to chronic pain and other neuropsychiatric components of FM, such as the ventrolateral thalamus, cortex motor, prefrontal cortex, insular cortex, hippocampus, periaqueductal gray matter, among others. The investigators believe that a higher cortico-thalamic IFC and between regions with high density of opioid receptors have a positive predictive response in the treatment of tDCS.
If the hypothesis is proven, the IFC data may serve as a biological marker associated with the perception of pain and its clinical presentation, and consequently, open the possibility of including IFC as a diagnostic parameter and therapeutic response. In addition to the possible contribution to knowledge production, this project aims to transfer the technology acquired and developed to the community, and thus benefit millions of people suffering from chronic FM pain with limited diagnostic and therapeutic perspectives, as well as extending the knowledge acquired for other neuropsychiatric disorders, such as depression.
- Conditions
- Fibromyalgia
- Being tested
- Active-tDCS, Sham-tDCS
- Keywords
- fibromyalgia, tDCS, fMRI, rs-fMRI
- Medical subject headings
- Fibromyalgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active-tDCSDevice
Active home-based tDCS applied at home. 5 days a week for 4 weeks.
Sham-tDCSDevice
Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Active-tDCS | Active comparator | 10 patients will receive Active-tDCS intervention (2mA, 20 min) at home. Receives: Device: Active-tDCS |
| Sham-tDCS | Sham comparator | 10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home. Receives: Device: Sham-tDCS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline Functional cerebral connectivity(rs-fMRI)to post-intervention rs-fMRI
Evaluation of functional cerebral connectivity using resting-state functional magnetic resonance imaging (rs-fMRI) between the change in baseline and post-intervention assessments.
Measured: 30 minutes
Secondary outcomes (1)
Structural cerebral connectivity
Evaluation of structural cerebral connectivity using diffusion tract imaging (DTI)
Measured: 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2019
- Study start1 Aug 2018
- Primary completion1 Dec 2019 (estimated)
- Study completion1 Mar 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- More trials run by Hospital de Clinicas de Porto AlegreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital de Clinicas de Porto Alegre
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wolnei Caumo, Hospital de Clinicas de Porto Alegre
- Investigators
- Wolnei Caumo, PhD, Principal investigator, Federal University of Rio Grande do Sul
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03841227
- Sponsor's protocol ID
- 2018-0353
- Status last verified
- Feb 2019
- First submitted
- 4 Aug 2018
- Last updated
- 15 Feb 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Transcranial Continuous Current Neuromodulation in Intrinsic Functional Brain Connectivity Assessed by Functional Magnetic Resonance Imaging (fMRI) in Fibromyalgia: A Randomized, Double-blind Controlled Trial
- ClinicalTrials.gov ID
- NCT03841227
- Acronym / sponsor ID
- 2018-0353
- Conditions
- Fibromyalgia
- Keywords
- fibromyalgia, tDCS, fMRI, rs-fMRI
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Hospital de Clinicas de Porto AlegreUniversity, hospital or other
- Study start
- 1 Aug 2018 (actual)
- Primary completion
- 1 Dec 2019 (estimated)
- Study completion
- 1 Mar 2020 (estimated)
- First posted
- 15 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Considering the central component of fibromyalgia (FM), the focus of research on current therapeutic approaches has been techniques that may modify the dysfunctional neuroplasticity process, such as transcranial direct current (tDCS) stimulation in order to counteract the dysfunction responsible for triggering and maintain the symptoms of FM. Although this technique is gaining space in research and in the clinical scenario, many questions remain to be answered, such as time of treatment, place to be stimulated and neurophysiological clarification of the mechanisms involved.
Based on the presented scenario, the present project was organized, being a double-blinded parallel randomized controlled trial with 20 female patients with FM diagnosed according to the criteria of the American Society of Rheumatology (2010 - reviewed in 2016) between 19 and 65 years of age, randomized to receive active or simulated anodic pole over the left dorsolateral prefrontal cortex (DLPFC) (10 patients in each group). Twenty 20-minute sessions, with a current intensity of 2 milliamperes, will be performed.
In order to respond to the objectives of this study, the IFC will be evaluated before and after the intervention, through rs-fMRI using seed-based correlation analysis (SCA). The investigators have a secondary objective to correlate structural connectivity through the technique of diffusion tensors imaging (DTI) with measures of pain, functional capacity, depressive symptoms and catastrophism to pain.
The hypothesis is that in FM there is a syndrome of dysfunction in basal intrinsic functional connectivity (IFC) and that the tDCS has a neuromodulatory effect capable of reducing connectivity between brain areas related to chronic pain and other neuropsychiatric components of FM, such as the ventrolateral thalamus, cortex motor, prefrontal cortex, insular cortex, hippocampus, periaqueductal gray matter, among others. The investigators believe that a higher cortico-thalamic IFC and between regions with high density of opioid receptors have a positive predictive response in the treatment of tDCS.
Detailed description
Fibromyalgia (FM) is a syndrome that is characterized by generalized musculoskeletal pain, fatigue, unrepairable sleep, cognitive alterations, depressive and neurovegetative symptoms, whose neurobiological process is multiple and complex. Although it is of great relevance to the individual and to society, this pathology often does not receive the necessary attention by the organs that define the priorities of health care. Population prevalence, according to the criteria of the American Society of Rheumatology, reaches 5.4%, and the costs of care, taxes and early retirement due to disability are estimated at more than the US $ 29 billion per year in the United States. It is known that conventional pharmacological therapies produce insignificant responses in more than 50% of patients. It is postulated that these high rates of failure are due in part to a lack of knowledge about pathophysiological mechanisms. What is known so far is that the peripheral mechanisms contribute to the FM picture, but dysfunction in central neurobiological pathways surely commands the process, perpetuating the dysfunctional process that includes central sensitization (CS). CS comprises the symptoms of fibromyalgia syndrome that culminates in a state of hypersensitivity that expresses the imbalance of the excitation/inhibition processes that sustain this condition of non-pathological pain. Functional alterations of the motor cortex and its connections with subcortical structures that constitute the neuromatrix of pain have now been demonstrated. Functional magnetic resonance imaging (fMRI), using the resting-state fMRI (rs-fMRI) technique, has also demonstrated that high intrinsic functional connectivity (IFC) is related to pain intensity on FM.
Considering the central component of FM, the focus of research on current therapeutic approaches has been techniques that may modify the dysfunctional neuroplasticity process, such as transcranial direct current (tDCS) stimulation in order to counteract the dysfunction responsible for triggering and maintain the symptoms of FM. Although this technique is gaining space in research and in the clinical scenario, many questions remain to be answered, such as time of treatment, place to be stimulated and neurophysiological clarification of the mechanisms involved.
Based on the presented scenario, the present project was organized, being a double-blinded parallel randomized controlled trial with 20 female patients with FM diagnosed according to the criteria of the American Society of Rheumatology (2010 - reviewed in 2016) between 19 and 65 years of age, randomized to receive active or simulated anodic pole over the left dorsolateral prefrontal cortex (DLPFC) (10 patients in each group). Twenty 20 minute sessions, with a current intensity of 2 milliampere, will be performed.
In order to respond to the objectives of this study, the IFC will be evaluated before and after the intervention, through rs-fMRI using seed-based correlation analysis (SCA). The investigators have a secondary objective to correlate structural connectivity through the technique of diffusion tensors imaging (DTI) with measures of pain, functional capacity, depressive symptoms and catastrophism to pain.
The hypothesis is that in FM there is a syndrome of dysfunction in basal IFC and that the tDCS has a neuromodulatory effect capable of reducing connectivity between brain areas related to chronic pain and other neuropsychiatric components of FM, such as the ventrolateral thalamus, cortex motor, prefrontal cortex, insular cortex, hippocampus, periaqueductal gray matter, among others. The investigators believe that a higher cortico-thalamic IFC and between regions with high density of opioid receptors have a positive predictive response in the treatment of tDCS.
If the hypothesis is proven, the IFC data may serve as a biological marker associated with the perception of pain and its clinical presentation, and consequently, open the possibility of including IFC as a diagnostic parameter and therapeutic response. In addition to the possible contribution to knowledge production, this project aims to transfer the technology acquired and developed to the community, and thus benefit millions of people suffering from chronic FM pain with limited diagnostic and therapeutic perspectives, as well as extending the knowledge acquired for other neuropsychiatric disorders, such as depression.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active-tDCS | Active comparator | Device: Active-tDCS10 patients will receive Active-tDCS intervention (2mA, 20 min) at home. |
| Sham-tDCS | Sham comparator | Device: Sham-tDCS10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Literate
- Female, between 18 and 65 years old
- With the diagnosis of fibromyalgia according to the criteria of the American College of Rheumatology (2010-2016)
- Pain score equal to or greater than six on the Numerical Pain Scale (NPS 0-10) on most days of the last 3 months.
- Give informed consent to participate after the initial evaluation.
Key exclusion criteria (5 listed)
- Living outside the city of Porto Alegre, RS, Brazil
- Pregnancy
- Severe Mental Illness
- tDCS contraindications
- Magnetic resonance imaging (MRI) contraindications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active-tDCSActive home-based tDCS applied at home. 5 days a week for 4 weeks. | Device | Active-tDCS |
| Sham-tDCSSham home-based tDCS applied at home. 5 days a week for 4 weeks. | Device | Sham-tDCS |
Primary outcome
Change from Baseline Functional cerebral connectivity(rs-fMRI)to post-intervention rs-fMRI
Time frame: 30 minutes
Evaluation of functional cerebral connectivity using resting-state functional magnetic resonance imaging (rs-fMRI) between the change in baseline and post-intervention assessments.
1 secondary outcome
Structural cerebral connectivity
Time frame: 30 minutes
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2019.
Related trials for Fibromyalgia
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wolnei Caumo, PhD principal investigator
Federal University of Rio Grande do Sul
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active-tDCS in people with Fibromyalgia, run by Hospital de Clinicas de Porto Alegre at 2 sites in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Wolnei Caumo, PhD (+5551 3359 8083, wcaumo@cpovo.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline Functional cerebral connectivity(rs-fMRI)to post-intervention rs-fMRI (time frame: 30 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2019.